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Background/aim: To evaluate acetylcholinesterase (AChE) inhibitory activity and antioxidant capacity of the major molecule from
Salvia sp., rosmarinic acid, as a drug candidate molecule for treatment of Alzheimer disease (AD).
Materials and methods: The AChE inhibitory activity of different extracts from Salvia trichoclada, Salvia verticillata, and Salvia
fruticosa was determined by the Ellman and isolated guinea pig ileum methods, and the antioxidant capacity was determined with
DPPH. The AChE inhibitory activity of the major molecule rosmarinic acid was determined by in silico docking and isolated guinea
pig ileum methods.
Results: The methanol extract of Salvia trichoclada showed the highest inhibition on AChE. The same extract and rosmarinic acid
showed significant contraction responses on isolated guinea pig ileum. All the extracts and rosmarinic acid showed high radical
scavenging capacities. Docking results of rosmarinic acid showed high affinity to the selected target, AChE.
Conclusion: In this study in vitro and ex vivo studies and in silico docking research of rosmarinic acid were used simultaneously for the
first time. Rosmarinic acid showed promising results in all the methods tested.
Key words: Salvia, rosmarinic acid, acetylcholinesterase, isolated guinea pig ileum, computational screening

1. Introduction
Alzheimer disease (AD) is characterized by loss of
cognitive function leading to dementia. The main
symptoms associated with AD involve a decline in cognitive
dysfunction, primary memory loss, and, in the later stages
of the disease, language deficits, depression, agitation,
mood disturbances, and psychosis (1). The pathological
features of AD include neurotic plaques composed of
amyloid-β-peptide (Aβ) cores, neurofibrillary tangles of
hyperphosphorylated tau protein, and neurotransmitter
deficits (2). Acetylcholine has a functional key role in
cognitive functions including learning and memory,
arousal, and attentional processes in the brain (3).
Acetylcholinesterase (AChE) is the key enzyme in the
breakdown of acetylcholine; therefore, the inhibition
of AChE is considered one of the treatment strategies
against several neurological disorders such as AD, senile
dementia, ataxia, and myasthenia gravis (4). AChE
* Correspondence: omurd@hacettepe.edu.tr

inhibitors are the only agents approved by the US Food
and Drug Administration for the treatment of AD. Within
the past few years, some synthetic compounds (tacrine,
rivastigmine, donepezil, and galanthamine) have become
available for clinical use; however, none of them have the
ability to stop the disease. Thus, there is still great urgency
for finding new drug candidates for AD treatment.
Several findings suggest that oxidative stress may play
an important role in the pathogenesis of AD. First, the
brains of patients with AD contain lesions that are typically
associated with exposure to free radicals. In addition,
oxidative stress in the brains of AD patients is indicated
by elevated cerebral levels of endogenous antioxidants that
scavenge free radicals (5).
Moreover, in vitro studies suggest that exogenous
antioxidants reduce the toxicity of Aβ in the brains of AD
patients. Antioxidants may decrease the level of oxidative
stress in the brain and thereby reduce the amount of DNA
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damage, neuronal cell death, and aggregation of Aβ within
the brain (5). Notably, oxidative stress leads to activation
of stress-activated protein kinases. One stress-activated
protein kinase in particular, p38 MAP kinase, appears
to be crucial in AD because it promotes tau protein
hyperphosphorylation (6).
In the 16th century Salvia officinalis was described as
being good for the memory. In clinical trials the ethanolic
extracts and volatile oils of S. officinalis and S. lavandulifolia
have been shown to be effective in mild scaled AD patients,
even in low doses (7–10). A previous study showed the
protective effect of Salvia officinalis extract and its active
ingredient rosmarinic acid on PC12 neuroblastoma cells
(11). The dried root of Salvia miltiorrhiza has been used
for the treatment of cerebrovascular disease and central
nervous system deterioration in old age for over 1000 years
(12).
The genus Salvia L. (Lamiaceae) is represented by over
900 species worldwide and by 99 species in the flora of
Turkey (13). A large number of secondary metabolites,
including essential oils, terpenoid compounds, and
phenolic derivatives, have been isolated from the genus,
and these feature prominently in the pharmacopoeias of
many countries throughout the world (14–16). Traditional
medicinal uses prompted us to investigate this herb
further. In our previous study the antiinflammatory effects
of 3 Salvia species were compared (17).
The aim of this study was to evaluate the
anticholinesterase and antioxidant effect of extracts of S.
trichoclada Benth., S. verticillata L., and S. fruticosa Mill.
(Lamiaceae) and their main active ingredient rosmarinic
acid by in vitro, ex vivo, and in silico methods.
2. Materials and methods
2.1. Plant material
The aerial parts of Salvia trichoclada Benth. were collected
from Hakkari - Yüksekova (A. Donmez, HUB 11036) in
June 2002. Those of S. fruticosa Mill. (syn. S. triloba) were
collected from Antalya - Kemer in April 2004 (P. Gurbuz,
HUEF 08014), and those of S. verticillata L. were harvested
from Ankara - Karagöl (L.O. Demirezer, HUEF 08011)
in June 2005. The voucher specimens of the plants were
deposited at the herbarium of the Hacettepe University
Faculty of Pharmacy (HUEF) and the herbarium of the
Hacettepe University Faculty of Science (HUB).
2.2. Chemicals and standards
2.2-Diphenyl-1-picrylhydrazyl
(DPPH),
(S)acetylthiocholine iodide, 5,5′-dithiobis(2-nitrobenzoic
acid) (DTNB, Ellman’s reagent), physostigmine, and
AChE (0.5 U/mg) derived from electric eels (AChE True
Cholinesterase, EC 3.1.1.7 Type VI-S) were purchased from
Sigma-Aldrich (Steinheim, Germany). Buffer components
and other chemicals were of the highest purity available
commercially and supplied by Carlo Erba (Milan, Italy).
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2.3. Extraction and isolation
Thirty grams of aerial parts of the plants were extracted
separately under reflux in a water bath with 150 mL of
acetone at 37 °C for 1 h. After filtration, acetone extracts
were evaporated under vacuum at 37 °C to dryness, and
the plant residue was extracted with 150 mL of methanol
and quantitatively filtered. After the evaporation process,
methanol extracts were suspended in 150 mL of water
and then extracted with 150 mL of chloroform and 150
mL of n-butanol respectively. Each extract was evaporated
separately under vacuum at 37 °C to dryness.
The isolation and structural elucidation of compounds
from Salvia species were reported previously (18) .
2.4. Preparation of the Salvia trichoclada volatile oil
The whole plant sample (100 g) was cut into small pieces
and subjected to hydrodistillation for 3 h using a Clevenger
type apparatus. The essential oil was dried over anhydrous
sodium sulfate, stored in a refrigerator, and protected from
light until further use.
2.5. Ellman method
The methanol, n-butanol, and water extracts of 3 genera
of Salvia were tested for their AChE inhibitory activities
at 0.1, 0.25, 0.5, 1.0, and 2.0 mg/mL concentrations.
The anticholinesterase potential of the extracts was
compared with physostigmine. Less than 50% inhibition
of AChE was not considered significant. Each assay was
conducted using the modified Ellman method (19). One
hundred and twenty microliters of DTNB (0.125 mM
in 50 mM phosphate buffer, pH 7.4), 120 µL of 0.5 mM
acetylthiocholine iodide (ATChl in bidistilled water), 600
µL of phosphate buffer (100 mM, pH 7.4), and different
concentrations of samples were dissolved in bidistilled
water, and 10% methanol was added to each cuvette. Each
reaction was started by adding 10 µL of 0.28 U/mL AChE
with a final concentration of 0.023 U/mL prepared in
phosphate buffer. Measurements were taken every second
for 2 min at 25 °C (εTNB, 412 nm = 14.2 mM–1 cm–1). The
assay was conducted on 3 separate samples of each extract.
Enzyme activity was calculated as a percentage of the
velocities as compared to assay using buffer without any
inhibitor. Inhibitory activity was calculated by subtracting
the percentage of enzyme activity from 100. Every
experiment was done in triplicate. Physostigmine (0.1
mM) was used as a standard AChE inhibitor in the study.
The inhibition rate (%) was calculated by the following
equation:
Inhibition % = 100 – (100 × VT / VK),
where VK is the velocity of the control without inhibitor
and VT is the velocity of the test solution.
2.6. Isolated guinea pig ileum method
Each animal was sacrificed by cervical dislocation. The
ileum was removed, prepared in 2-cm lengths, mounted in
10-mL tissue baths containing Tyrode’s solution maintained
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at 37 °C, and aerated with a mixture of carbon dioxide
(5%) and oxygen (95%). The cumulative concentration–
response of acetylcholine (10–8 to 10–4 M) was constructed
with the presence of a vehicle as a control. Each tissue
sample was washed every 15 min for a 1-h equilibrium
period. The cumulative concentration–response curves
of acetylcholine (10–8 to 10–4 M) were constructed for
comparison of the presence of crude extract (100 μg/mL)
and/or of the physostigmine standard (0.01–0.1 µM). Each
plant extract was examined for spasmogenic activity.
All experimental data are presented as mean ± standard
deviation. Analysis was performed using the GraphPad
Prism statistical software package (version 3.03) and P <
0.05 was considered statistically significant.
2.7. Ethical aspects
All rats used in the present study were cared for in
accordance with the directory of the Hacettepe University
Animal Care Unit, which applies the guidelines of the
National Institutes of Health on laboratory animal welfare.
2.8. Free radical DPPH scavenging assay
Two hundred and thirty microliters of methanol extracts
(400, 200, 100, 50, 25 µg/mL) was added to 50 µL of a
0.022% methanolic solution of DPPH. After a 30-min
incubation period at room temperature, the absorbances
were read against a blank at 517 nm. Inhibition of free
radical DPPH in percent (I%) was calculated as follows:
I% = (Ablank – Asample / Ablank) × 100.
Tests were carried out in duplicate. Ascorbic acid was
used as a standard substance (20,21).
2.9. Molecular docking studies
2.9.1. Target identification
In this study, AChE was selected as a target and then
computationally determined, and relative binding energies
to rosmarinic acid, gallic acid, ascorbic acid, physostigmine,
galanthamine, and huperzine A and their docking results
were compared. Physostigmine, galanthamine, and
huperzine A are currently being evaluated for their clinical
efficacy in the management of AD and vascular dementia.
Gallic and ascorbic acids are strong antioxidant molecules.
The 3-dimensional structures of ACE (3LII) were obtained
from the Protein Data Bank (PDB). These structures were
determined using X-ray diffraction. The 3-dimensional
structures of the targets were downloaded from the RCSB
PDB. All solvent molecules and cocrystallized ligands
were removed from the structures.
2.9.2. Ligand identification
The PDB files of rosmarinic acid and physostigmine were
obtained by using the Discovery Studio 3.5 Client program.
The 3-dimensional structures of these compounds were
drawn and then converted into PDB format by using
this program. The 3-dimensional structures of huperzine
A (4EY5) and galanthamine (4EY6) were obtained from

the PDB. The 3-dimensional structures of ligands were
downloaded from the RCSB PDB.
2.9.3. Docking receptors with rosmarinic acid using
AutoDock Vina
AutoDock Vina 1.0 beta 0.2 software was used to search
for the potential targets of rosmarinic acid. The graphical
user interface program AutoDock Tools was used to
prepare, run, and analyze the docking simulations. Atom
charges, solvation parameters, and polar hydrogens were
added to the receptor PDB file for the preparation of
protein in docking simulations. AutoDock Vina (22–24)
requires precalculated grid maps. This grid must contain
the potential binding region of the target we are interested
in. The grid box size was set at 20, 20, and 20 Å (x, y, and
z). The spacing between grid points was 1.0 Å. After the
simulations were completed, the docked structures were
studied and the interactions were analyzed. Hydrogen
bond interactions and the binding distance between
the donors and acceptors were measured for the best
conformers. AutoDock was run with the Windows XP
operating system and all the AutoDock docking runs were
performed 3 times. Finally, AutoDock Vina stored the
potential energy arising from the interaction of flexible
targets with rigid macromolecules.
3. Results
3.1. Ellman method
Methanol, n-butanol, and water extracts were prepared
(0.1, 0.25, 0.5, 1.0, and 2.0 mg/mL) and tested for their
AChE inhibitory activities. The anticholinesterase
potential of the extracts was compared with the positive
control of physostigmine.
Less than 50% inhibition of AChE was not considered
significant. The methanol extract of Salvia trichoclada
inhibited AChE at a rate of ±81.10% at a concentration of 2
mg/mL, while other concentrations and methanol extracts
of S. verticillata and S. fruticosa showed lower inhibition
(Table 1).
3.2. Isolated guinea pig ileum method
Acetylcholine (10–9 to 10–4 M) elicited concentrationdependent contraction in isolated guinea pig ileum.
Physostigmine (0.01–0.1 µM) (P = 0.072; one-way
ANOVA) (Figure 1) and the methanol extract of S.
trichoclada (100 μg/mL) (10-6 to 10-4 M; Student t-test,
P = 0.0454; n = 6) (Figure 2) potentiated the effect of a
cumulative dose response (contraction) of acetylcholine
(10–8 to 10–4 M) in a dose-dependent fashion, suggesting
an AChE inhibitory effect. The methanol extract of Salvia
trichoclada showed better contraction response than other
studied Salvia species, while their acetone extracts showed
no inhibitory effects (Figures 2 and 3).
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Table 1. Acetylcholinesterase inhibitions (%) and standard deviations of Salvia extracts (C in mg/mL) by Ellman method. *nd: Not
detectable.

C
2
1
0.5
0.25
0.1

Salvia trichoclada

Salvia fruticosa

Salvia verticillata

n-BuOH

Water

MeOH

n-BuOH

Water

MeOH

83.85 ±
2.7449
62.93 ±
1.1579
45.68 ±
1.9374
30.51 ±
0.2969

81.52 ±
0.4010
74.31 ±
1.4931
62.69 ±
1.9294
23.69 ±
2.1819
27.75 ±
1.8066

81.10 ±
2.6375
71.62 ±
0.8909
63.81 ±
0.5727
57.39 ±
1.8031
29.85 ±
0.7926

72.11 ±
2.4448
47.84 ±
0.4813
33.79 ±
1.7182
21.19 ±
2.2312

70.5 ±
4.9797
52.00 ±
2.00
36.50 ±
2.1213
21.00 ±
2.0000
11.5 ±
2. 1213

44.52 ±
4.1577
25.42 ±
1.5344
15.57 ±
0.9036
10.75 ±
1.5909
4.80 ±
0.1524

nd

nd

n-BuOH
nd*
43.55 ±
0.8297
27.04 ±
4.3345
16.52 ±
2.6311
6.35 ±
0.9192

Water

MeOH

12.23 ±
1.1773
12.95 ±
0.7848
9.86 ±
0.7848
5.42 ±
1.5344

28.29 ±
1.5505
15.74 ±
0.3394
13.52 ±
0.5036
9.01 ±
0.7141
7.25 ±
0.1767

nd

Figure 1. Concentration-dependent contraction responses elicited by acetylcholine
(Ach) before (control) and after incubation of physostigmine standard (0.01–0.1 µM)
and rosmarinic acid (RA) (100 µg/mL). *, +, #: significantly different from control.

Figure 2. Concentration-dependent contraction responses elicited by acetylcholine (Ach) before (control)
and after incubation of methanol extract of S. fruticosa (Sf), S. verticillata (Sv), S. trichoclada (Str), and
volatile oil (VO) (100 µg/mL). * Significantly different from control for Str, + for Sf, # for Sv, & for VO.

3.3. Free radical DPPH scavenging assay
Rosmarinic acid showed 90.58% and 90.40% DPPH activity
at 200 μM and 100 μM concentrations (IC50 = 24.38), while
ascorbic acid showed 91% and 90% and α-tocopherol 88%
and 90% DPPH activity.
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3.4. Molecular docking studies
According to the docking results of rosmarinic acid (Figure
5), the binding energies of rosmarinic acid, galanthamine,
huperzine A, and physostigmine to AChE were –8.0, –7.7,
–7.5, and –7.0 kcal/mol, respectively (Table 2).
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Figure 3. Concentration-dependent contraction responses elicited by acetylcholine
(Ach) before (control) and after incubation of acetone extracts of Str, Sv, and Sf
(100 µg/mL). + Significantly diffrent from control for Str, * for Sv, & for Sf.

4. Discussion
Natural products have been used empirically since
ancient times and a tendency is appearing today for their
increased usage. The pharmaceutical industry requires
potential novel drug candidate molecules. To date, no
molecules could be synthetized without patterning a
natural model. Therefore, the isolation of model molecules
from natural sources has been very important. Salvia
sp. is a common aromatic and medicinal plant native to
Mediterranean countries and is in widespread use. As
mentioned in the introduction, many studies have been
carried out on Salvia officinalis, S. lavandulifolia, and S.
miltiorrhiza. In this study, 3 different Salvia species, S.
trichoclada, S. verticillata, and S. fruticosa, which grow
in the Mediterranean area, were selected for guided
investigation of biological activity.
In the first step, in vitro AChE inhibitory activity of
the extracts from 3 Salvia species were studied using the
colorimetric method of Ellman et al. (19).
Secondly, an ex vivo study was carried out on isolated
guinea pig ileum. The enteric nervous system, which
runs along the length of the gastrointestinal tract, plays
an important role in coordinating the motor activity of
the muscular layers. The dominant excitatory enteric
neurotransmitter is thought to be acetylcholine. Two
different enzymes that hydrolyze acetylcholine have been

Figure 4. Rosmarinic acid.

described in the mammalian small intestine: AChE and
butyrylcholinesterase (BuChE). AChE is the main enzyme
responsible for the inactivation of acetylcholine, whereas
the physiological function of BuChE remains unknown.
In the present study, we determined the possible
inhibitory effects of Salvia extracts on AChE in isolated
guinea pig ileum preparation, and we compared them with
that of physostigmine, which is reported to inhibit AChE.
In the present experimental conditions, peristalsis of the
isolated guinea pig ileum persisted constantly during
the experimental period. During the 10-min incubation
period, none of the extracts significantly altered peristalsis
of the isolated guinea pig ileum. The crude extracts of
Salvia species did not cause a dose-dependent (100 μg/
mL) spasmogenic effect in the isolated guinea pig ileum.

Figure 5. Molecular docking of rosmarinic acid in the active site
of AChE.
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Table 2. In silico docking results of rosmarinic acid (AChE).
Ligand

AutoDock Vina
3LII (AChE)

Rosmarinic acid

–8

Galanthamine

–7.7

Physostigmine

–7.0

Huperzine A

–7.5

The volatile oil of Salvia lavandulifolia (Spanish sage)
has been found to be an uncompetitive reversible inhibitor
(10). Therefore, the volatile oil of Salvia trichoclada (100
μg/mL) was also investigated. As shown in Figure 2,
volatile oil completely blocked the acetylcholine-induced
contraction in isolated guinea pig ileum.
Furthermore, because the 10-min incubation period
was not sufficient for enzyme induction, we suggest
that inhibition of the contractile response might not be
dependent on AChE induction. However, we speculated
that the above-mentioned extracts are likely to have
antagonistic activity against muscarinic receptors and
these compounds are likely to compete with acetylcholine
against muscarinic receptors. Further studies are necessary
on this point.
As seen from the data, the Ellman and the isolated
guinea pig ileum methods verified each other.
Free radicals cause various diseases including AD (5),
and therefore the antioxidant effects of Salvia extracts
were tested by the DPPH method. In our previous study,
n-butanol, water, methanol, acetone, and chloroform
extracts of 3 Salvia species were tested at 1, 5, 10, 25, 50,
and 100 μg/mL. The results of the methanol extract of
S. trichoclada, S. fruticosa, and S. verticillata at 100 μg/
mL concentrations were 89.65%, 88.21%, and 86.05%,
respectively (18). In a recent study, DPPH radical scavenging
activities of CH2Cl2 and EtOH extracts of aerial parts from
S. verticillata subsp. amasiaca were investigated. The EtOH
extracts at 1000 μg/mL showed 81% inhibition (25). The
results were similar to our findings but we represented this
inhibition rate at a 100 μg/mL concentration. This may
be due to the different extract preparation procedures. In
another study, the DPPH radical scavenging effects of S.
fruticosa and S. trichoclada were tested. According to that
study the DPPH radical scavenging effects were 93% and
89% at 100 μg/mL, respectively (26). These results are also
consistent with ours.
When the results of the DPPH, Ellman, and isolated
guinea pig ileum methods were evaluated, it was seen that
the methanol extract of S. trichoclada showed the best
results.
The results showed us that the methanol extract
of S. trichoclada has both AChE inhibitory effects and
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antioxidant capacity. Based on these findings we want to
determine active molecules that can be evaluated as drug
candidates.
In recent times, computational (in silico) methods
including database search algorithms, determination of
quantitative structure–activity relationships, similarity
search methods, computational modeling, and docking
have been developed and widely applied to pharmacological
hypothesis development and testing. These methods have
been widely used to investigate potential drug targets
and understand absorption, distribution, metabolism,
excretion, and toxicity properties as well as for the
physicochemical characterization of drugs for the related
receptors and enzymes. To reduce the cost of drug
development and save time, in silico methods can be used
to make preliminary assessments and screening before in
vitro and in vivo research.
In our previous, study the major compound α-Ocafeoyl-3′,4′-dihydroxyphenyl lactic acid (rosmarinic
acid) (Figure 4) was isolated from the methanol extract of
Salvia trichoclada and its structure was elucidated by 1H
and 13C NMR (18).
According to some reports (27), rosmarinic acid
inhibited AChE moderately (47.3%) at doses of 1.0 mg/
mL using the Ellman method. In this study, an in silico
docking investigation of the interaction of rosmarinic acid
with the enzyme was performed. Molecular docking is
one of the most important parts of the in silico method.
We used AutoDock Vina along with database search
algorithms such as PDB sum and RCSB PDB and it
requires precalculated grid maps, one for each atom type
present in the flexible molecules being docked. Its stores
the potential energy arising from the interaction with rigid
macromolecules. This grid must surround the region of
interest in the grid macromolecule. The spacing between
grid points was 1.0 Å. After the dockings were complete,
the docked structures were analyzed and the interactions
were seen. Hydrogen bond interactions between the ligand
and enzymes were measured as binding energies and the
results gave us some ideas for the experimental part of
study. AChE is inhibited by a number of structurally very
diverse ligands including, for example, physostigmine,
huperzine A, and galanthamine, which are strong AChE
inhibitors. In this part of the study AChE was selected as the
target and then its relative binding energies to rosmarinic
acid, physostigmine, galanthamine, and huperzine A
were computationally determined and the docking
results were compared. As seen from the data, rosmarinic
acid showed the lowest binding energy. This means that
rosmarinic acid is more effective than galanthamine,
huperzine A, and physostigmine. To verify in silico
results, the anticholinesterase activity of rosmarinic acid
was investigated on isolated guinea pig ileum. As shown
in Figure 1, rosmarinic acid did not affect the contraction
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response elicited by acetylcholine in isolated guinea pig
ileum.
Different plant genera are an important source of
rosmarinic acid (28). Inhibition of glutathione reductase
and glucose 6-phosphate dehydrogenase antioxidant
enzymes by rosmarinic acid was shown in our previous
study (29). Thus, the antioxidant and AChE inhibitory
effects of rosmarinic acid were found to be significant with
in vitro and ex vivo methods.
In this study in vitro, ex vivo, and in silico methods
were used simultaneously for rosmarinic acid for the

first time and rosmarinic acid showed significant results
with these methods. Our results suggest that rosmarinic
acid may become a novel therapeutic candidate for the
treatment of AD.
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